Sagimet Biosciences Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| SGMT | IVA | SABS | VSTM | SLDB | DMAC | |
|---|---|---|---|---|---|---|
| Market cap | 624.00M | 737.01M | 257.49M | 747.15M | 719.48M | 442.19M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -6.8 | -4.2 | -3.0 | -11.0 | -3.9 | -10.1 |
| Price/book | 2.1 | -18.2 | 1.1 | 8.9 | 1.9 | 11.5 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +17.50% | −31.45% | +29.00% | −9.80% | +14.31% | +19.71% |
| Today | −1.46% | −1.27% | −5.03% | −1.55% | −2.33% | −1.56% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All SGMT news ›CEO of Sagimet Biosciences shares where denifanstat could fit in acne treatment | 2026 Fall Clinical Derm
Sagimet CEO David Happel says oral denifanstat could sharply cut antibiotic use in acne and be used before patients ever need isotretinoin. Denifanstat, an investigational once-daily oral pill from Sagimet Biosciences, more than doubled…
Analysts Have Conflicting Sentiments on These Healthcare Companies: Sanofi (OtherSNYNF), Sagimet Biosciences, Inc. Class A (SGMT) and Eli Lilly & Co (LLY)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Sanofi (SNYNF), Sagimet Biosciences, Inc. Class A (SGMT) and Eli Lilly & Co (LLY). In a report released today, Trung Huynh from RBC Capital…
Denifanstat Sustains Acne Improvement Through 52 Weeks in Phase 3 Extension Study
Oral denifanstat, a once-daily fatty acid synthase (FASN) inhibitor under development for moderate to severe acne vulgaris, demonstrated sustained efficacy through 52 weeks in a Phase 3 open-label extension study. The findings showed 57%…
Sagimet Biosciences: Commodore reports 7.6% ownership
The 5,507,752-share position includes 2,757,742 common shares and 2,750,010 shares acquirable through pre-funded warrants, subject to the cap. - [SCHEDULE 13G] Sagimet Biosciences Inc. Passive Investment Disclosure (>5%) Sagimet…
David Happel of Sagimet talks about what denifanstat must prove in the U.S. | 2026 Fall Clinical Derm
Sagimet CEO David Happel shares insights on denifanstat, highlighting strong acne response, tolerability and optimism for a denifanstat U.S. trial. Sagimet Biosciences has begun screening patients for a U.S. phase 3 trial of denifanstat,…
Cantabria Labs Difa Cooper doubles down on trichology and dermocosmetics, EBITDA at 19%
News business : The Italian cosmetics company is presenting the Trichology Observatory 2026, launching new products for four of its brands and raising the share of dermatological products in its turnover to 50%.
Biofrontera Submits sNDA to Expand Ameluz PDT for Actinic Keratoses Across the Body
Ameluz PDT is currently FDA approved for the treatment of AKs on the face and scalp and, as of September 2026, for superficial basal cell carcinoma. According to Biofrontera, approval of the latest application would make Ameluz with red…
Sagimet To Present Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne and Mechanistic Data at the 2026 Fall Clinical Dermatology Conference
MINERAL EUROPA: A GAME CHANGER FOR SHIPPING The extension reported continued efficacy through 52 weeks as Sagimet’s U.S. Phase 3 AURORA trial begins patient screening. Sagimet Biosciences (SGMT) announced 52-week acne results from license…
Versant Diagnostics Acquires American Dermatopathology Laboratory, LLC, and Welcomes Distinguished Dermatopathologist H. Nicholas Shamma, MD
ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness. “We are honored to have Dr. Shamma on our team,” said ... “I could not be more excited to…
Biofrontera Submits Supplemental New Drug Application to FDA to Expand Ameluz® Red Light PDT to Actinic Keratoses on the Full Body
The Phase 3 trial reported complete lesion clearance in 45.6% of Ameluz patients versus 16.7% with vehicle treatment. A randomized, vehicle-controlled Phase 3 trial enrolled 172 patients. Complete clearance of all treated lesions 12 weeks…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Most coverage from
-
stocktitan.net4
-
seekingalpha.com2
-
themarketsdaily.com2
-
grafa.com1
-
markets.businessinsider.com1
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 14 articles, not a forecast.